Cizzle Biotechnology Holdings plc (LON:CIZ), a UK based developer of a blood test for the early detection of a majority of different forms of lung cancer, has today announced the Company’s Annual Report for the year ended 31 December 2020 and the Notice of Annual General Meeting have now been published on the Company’s website at cizzlebiotechnology.com. A letter has been dispatched to all shareholders explaining the arrangements for the AGM together with hard copies of the 2020 Annual Report and Notice of AGM to any shareholders who have elected to receive them.
Annual General Meeting
The Annual General Meeting will be held at 11:00am on Tuesday 29th June 2021 at the offices of Goodman Derrick LLP, 10 St Bride Street, London, EC4A 4AD.
At the time of writing the current issues surrounding COVID-19 (coronavirus) and the current guidance from the UK Government is that indoor public gatherings are not permitted, which include attending a AGM. The health and safety of our shareholders and colleagues is always our utmost priority. At the time of writing it remains uncertain as to whether the guidance will be relaxed to allow physical attendance at the AGM. Therefore please note that if the public health guidance remains unchanged shareholders are advised not to attend the AGM in person and those that attend the venue may be denied entry. Therefore, we strongly encourage you to consider ensuring your vote is counted by submission of a proxy form in accordance with the notes set out within the Notice of Meeting. All shareholders are urged to appoint the Chairman of the meeting as their proxy, with voting instructions.
Although this outcome is undesirable, the directors of Cizzle Biotechnology Holdings plc believe that, in the current circumstances, there is no alternative to ensure the health, safety and security of attendees and to allow the business of the AGM to be transacted. We will continue to monitor the situation and the latest available public health guidance, and will provide updates in relation to our AGM on our website as and when necessary.
Should you wish to raise any questions ahead of the meeting please do so via email to the Company at [email protected]. We will endeavour to respond to all questions received by 5pm on Friday 23 June 2021 with any relevant Q&A being published on the Company website prior to the meeting.
